REG - BiVictriX Therapcts. - Director Dealing

Bivictrix TherapeuticsAnnouncement

02/09/2024 09:00

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20240902:nRSB5009Ca&default-theme=true

RNS Number : 5009C  BiVictriX Therapeutics PLC  02 September 2024

THIS ANNOUNCEMENT CONTAINS INSIDE INFORMATION AS STIPULATED UNDER THE UK
VERSION OF THE MARKET ABUSE REGULATION NO 596/2014 WHICH IS PART OF ENGLISH
LAW BY VIRTUE OF THE EUROPEAN (WITHDRAWAL) ACT 2018, AS AMENDED.  ON
PUBLICATION OF THIS ANNOUNCEMENT VIA A REGULATORY INFORMATION SERVICE, THIS
INFORMATION IS CONSIDERED TO BE IN THE PUBLIC DOMAIN.

 

 

BIVICTRIX THERAPEUTICS PLC

("BiVictriX" or "the Company")

 

Director Dealing

 

Alderley Park,  2 September 2024 BiVictriX Therapeutics plc (AIM: BVX), a
drug discovery and development company applying an innovative, proprietary
approach to develop a new class of highly selective, next generation cancer
therapeutics, bispecific antibody drug conjugates (Bi-Cygni® ADCs), which
exhibit superior potency, whilst reducing treatment-related toxicities,
announces the following dealing in the  Company's ordinary shares of 1 pence
each ("Ordinary Shares").

 

On 30 August 2024, Mr Robert Hawkins, a Non-Executive Director, carried out a
'Bed and ISA' transfer of20,000 Ordinary Shares from his ISA account into a
share dealing account (the "Transfer"). The shares were sold for 7.26 pence
per Ordinary Shares and immediately repurchased at 7.92 pence per Ordinary
Share.

 

Following the Transfer, Robert Hawkins remains beneficially interested in
325,000 Ordinary Shares which equates to 0.39 per cent. of the Company's total
issued share capital.

 

ENDS

 

 BiVictriX Therapeutics plc

 Tiffany Thorn, Chief Executive Officer                         Email: info@bivictrix.com (mailto:info@bivictrix.com)

 Michael Kauffman, Non-Executive Chairman

 SP Angel Corporate Finance LLP (NOMAD and Broker)
 David Hignell, Caroline Rowe (Corporate Finance)

Vadim Alexandre, Rob Rees (Sales and Broking)                Tel: +44 (0) 20 3470 0470

 Panmure Liberum Limited (Joint Broker)
 Emma Earl, Freddy Crossley, Mark Rogers, Rupert Dearden

                                                               Tel: +44 (0) 20 3100 2000

 ICR Consilium

 Namrata Taak, Lucy Featherstone, Max Bennett, Emmalee Hoppe   Tel: +44 (0) 20 3709 5700

                                                               Email: Bivictrix@consilium-comms.com (mailto:Bivictrix@consilium-comms.com)

 

 

About BiVictriX Therapeutics plc

BiVictriX (AIM: BVX) is an emerging biotechnology company leveraging clinical
experience and its proprietary discovery engine to advance a new class of
highly cancer-selective, next-generation precision cancer therapies in one of
the fastest-growing markets in oncology. BiVictriX's first-in-class Bi-Cygni®
Antibody Drug Conjugates ("ADCs") combine superior efficacy
with substantially improved cancer-selectivity and safety to provide
opportunities for prolonged dosing and greater efficacy in the clinic. The
Company is advancing its pipeline to deliver the future of cancer care across
a broad range of haematological and solid cancer indications in areas of high
unmet medical need.

 

Find out more at www.bivictrix.com (http://www.bivictrix.com/)  and connect
with us on LinkedIn
(https://www.linkedin.com/company/bivictrix-therapeutics-plc/)  and
Twitter @BiVictriX (https://twitter.com/BiVictriX) .

 

 

Notification and public disclosure of transactions by persons discharging
managerial responsibilities and persons closely associated with them.

 1.    Details of the person discharging managerial responsibilities / person closely
       associated
 a)    Name                                                         Robert Hawkins
 2.    Reason for the Notification
 a)    Position/status                                              Non-Executive Director
 b)    Initial notification/Amendment                               Initial notification
 3.    Details of the issuer, emission allowance market participant, auction
       platform, auctioneer or auction monitor
 a)    Name                                                         BiVictriX Therapeutics plc
 b)    LEI                                                          213800ZI85IZNA6N3L53
 4.    Details of the transaction(s): section to be repeated for (i) each type of
       instrument; (ii) each type of transaction; (iii) each date; and (iv) each
       place where transactions have been conducted
 a)    Description of the Financial instrument, type of instrument  Ordinary Shares of 1 pence each

                                                                    GB00BNXH3K91
       Identification code
 b)    Nature of the transaction                                    (i)            Sale of 20,000 Ordinary Shares from ISA account

                                                                    (ii)           Purchase of 20,000 Ordinary Shares from share dealing
                                                                    account

 c)    Price(s) and volume(s)                                       Price(s)                              Volume(s)
                                                                    (i)            7.26 pence             20,000

                                                                    (ii)           7.92 pence             20,000

 

 d)    Aggregated information:                                       N/A single transaction

       -  Aggregated volume

       -  Price
 e)    Date of the transaction                                      30 August 2024
 f)    Place of the transaction                                     AIM, London Stock Exchange

 

 

d)

Aggregated information:

-  Aggregated volume

-  Price

 N/A single transaction

e)

Date of the transaction

30 August 2024

f)

Place of the transaction

AIM, London Stock Exchange

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  DSHDZGGLNZLGDZG